Fig. 2: ctDNA dynamics and survival outcome. | npj Breast Cancer

Fig. 2: ctDNA dynamics and survival outcome.

From: Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Fig. 2

a VAF changes of 79 detected mutations from baseline to C2D1. p-value was calculated with Wilcoxon rank sum test. b Illustration of a case and its mVAFR. c Distribution plot of patients with mVAFR-low (mVAFR of ≤0.3), mVAFR-medium [mVAFRmed] (mVAFR of 0.31–0.99) and mVAFR-high (mVAFR of ≥1.0). d PFS based on ctDNA dynamics. e PFS based on ctDNA dynamics after combining the VAFR-low and ctDNA-low groups. f PFS hazard ratio forest plots across 4 different methods of assessing mVAF as a continuous variable: mVAF baseline, mVAF at C2D1, absolute change of mVAF between baseline and C2D1 and mVAFR of all mutations with a VAF ≥ 0.4 at baseline or C2D1. g Distribution of the intrinsic subtypes in the mVAFR-low group (n = 4 Luminal A [LumA], n = 4 Luminal B [LumB], n = 3 non-available tissue [NA]), mVAFR-medium/high group (n = 2 LumA, n = 4 LumB, n = 2 HER2-Enriched [HER2E], n = 2 Normal-like, n = 1 Basal-like, n = 9 NA) and ctDNA-low group (n = 2 LumA, n = 2 LumB, n = 2 HER2E, n = 2 Normal-like, n = 7 NA).

Back to article page